Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2020 Oct 01;: Authors: Cheson BD, Bartlett NL, LaPlant B, Lee HJ, Advani RJ, Christian B, Diefenbach CS, Feldman TA, Ansell SM Abstract BACKGROUND: Hodgkin lymphoma is potentially curable. However, 15-35% of older patients (ie, >60 years) have a lower...
Mon Oct 05, 2020 13:30
Health Care Professionals' Knowledge and Attitudes Toward Physical Activity in Cancer Patients: A Systematic Review. Semin Oncol Nurs. 2020 Sep 30;:151070 Authors: Alderman G, Semple S, Cesnik R, Toohey K Abstract OBJECTIVES: The purpose of this study was to, combine current available literature across health professionals to determine commonalities and differences between knowledge and attitudes of physical activity (PA) and its importance...
Mon Oct 05, 2020 13:30
Genome-wide association study of cardiovascular disease in testicular cancer patients treated with platinum-based chemotherapy. Pharmacogenomics J. 2020 Oct 03;: Authors: Steggink LC, Boer H, Meijer C, Lefrandt JD, Terstappen LWMM, Fehrmann RSN, Gietema JA Abstract Genetic variation may mediate the increased risk of cardiovascular disease (CVD) in chemotherapy-treated testicular cancer (TC) patients compared to the general population. Involved...
Mon Oct 05, 2020 13:30
No comments:
Post a Comment